この製品に関するご意見・ご照会・お問合せはこちら

Treatment of Cancer Improved by Combination Therapy Regimen

The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC). Besides, A new preclinical study suggests that combining immune checkpoint inhibitors targeting PD-1/ PD-L1 with MAPK-targeted therapy—drugs typically used separately— may help overcome cancer treatment resistance.

More and more studies have shown that immune checkpoint combination therapy has a good effect in dealing with cancer.

ACROBiosystems has developed an exclusive immune checkpoint protein collection. 

Product Features：

• High purity verified by MALS or HPLC.
• High bioactivity verified by ELISA/SPR/FACS, etc.
• High batch to batch consistency by strict QC
   tested

Main Applications：

      Immunization and antibody screening

      Cell-based assay

      Pharmacokinetic analysis

Wonder how can these immune checkpoint proteins help your drug development?

Assay Data

The protocols are available for free!

• Authentic structure verified by SEC-MALS

Figure 1. The purity of Human CD27 Ligand, His, Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Da) was more than 95% in HP-SEC, and around 55-70 kDa verified by SEC-MALS. 

• Cell-based assay

Flow Cytometry assay shows that Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) can bind to 293 cells overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).